Mankind Pharma reported a 17% year-on-year revenue growth to ₹14,278 crore for FY2026, driven by its core business and BSV acquisition. However, profit after tax saw a slight dip due to increased depreciation and finance costs.
Mankind Pharma FY2026 Results
Consolidated Revenue: ₹14,278 crore (17% YoY growth)
Consolidated Profit After Tax (PAT): ₹1,938 crore
Reader Takeaway: Revenue momentum strong from acquisitions, but margins pressured by higher costs.
What just happened
Mankind Pharma announced its consolidated financial results for the fiscal year ending March 31, 2026. The company reported a 17% year-on-year increase in consolidated revenue, reaching ₹14,278 crore. Domestic revenue contributed ₹12,217 crore, marking a 14.4% rise. However, consolidated Profit After Tax (PAT) saw a marginal decrease to ₹1,938 crore from ₹2,007 crore in the previous fiscal year. This decline was attributed to higher depreciation and finance costs, partly linked to the Bharat Serums and Vaccines (BSV) acquisition.
The Adjusted EBITDA margin stood at 25.4%, with reported EBITDA at ₹3,499 crore. Cash flow from operations was robust at ₹3,121 crore.
Why this matters
This performance indicates Mankind Pharma's ability to scale its business, successfully integrating acquisitions like BSV. The revenue growth signals strong market traction for its products. However, the dip in PAT highlights the immediate cost impact of expansion strategies, particularly finance and depreciation expenses. Investors will be keen to see how the company manages these costs and translates revenue growth into improved profitability.
The backstory
The company's strategy involves a shift from volume-led sales to a focus on chronic and specialty segments. The acquisition of BSV in October 2024 was a key event aimed at bolstering this strategy and revenue base. The company has been progressively increasing its share in chronic therapies.
What changes now
Mankind Pharma will likely focus on optimizing costs and driving synergies from the BSV acquisition to improve its profit margins. The company is also progressing towards its target of increasing its chronic therapy share. The reappointment of Mr. Satish Kumar Sharma as Whole Time Director for another five years signals continuity in leadership. The upcoming 35th AGM on August 4, 2026, will be a platform for further strategic discussions.
Risks to watch
Key risks include continued margin pressure from R&D and finance costs, and the successful integration of acquired businesses to achieve expected synergies. Any failure to manage these rising costs could further impact profitability.
Peer comparison
While specific peer comparisons are not detailed in the filing, Mankind Pharma's revenue growth of 17% indicates it is performing competitively within the Indian pharmaceutical sector, which generally sees steady growth driven by domestic demand and specialty segments.
Context metrics (time-bound)
- Consolidated Revenue FY2026: ₹14,278 crore (vs. ₹12,207 crore FY2025)
- Domestic Revenue FY2026: ₹12,217 crore (vs. ₹10,679 crore FY2025, approx. 14.4% growth)
- Consolidated PAT FY2026: ₹1,938 crore (vs. ₹2,007 crore FY2025)
- Adjusted EBITDA Margin FY2026: 25.4%
- Cash Flow from Operations FY2026: ₹3,121 crore
What to track next
Investors should monitor the company's progress in integrating BSV, its ability to improve EBITDA margins, and its market share growth in chronic and specialty segments. The company's performance in the next fiscal year will be crucial to assess the long-term impact of its recent acquisition and strategic shifts.